MarketPulse

fasedienol

17 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

VTGN Investors Face March 16 Deadline in Securities Fraud Class Action

Securities class action filed against VTGN alleges misleading statements about fasedienol drug and PALISADE-3 trial. Investors must act by March 16, 2026 deadline.
VTGNPhase 3 clinical trialsecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Vistagen Hit with Securities Fraud Lawsuit Over Fasedienol Trial Data

Class action lawsuit filed against $VTGN alleges securities fraud over misleading statements about fasedienol drug candidate and PALISADE-3 clinical trial data.
VTGNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Vistagen Investors Pursue Securities Fraud Claims Over Misleading Drug Trial Statements

Schall Law Firm seeks Vistagen investors in class action over alleged false statements regarding fasedienol drug candidate's Phase 3 trial prospects.
VTGNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Investors Face March 16 Deadline in Securities Lawsuit Over Trial Disclosures

Rosen Law Firm urges Vistagen investors to join securities class action by March 16, 2026, over alleged misstatements regarding fasedienol and clinical trials.
VTGNsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Vistagen Faces Class Action Over Alleged Misstatements on Fasedienol Trial Data

Class action lawsuit filed against $VTGN alleging securities fraud over fasedienol drug trial statements and concealed adverse clinical data.
VTGNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Securities Lawsuit: Investors Face March 16 Deadline in PALISADE-3 Trial Dispute

Vistagen faces securities fraud lawsuit over fasedienol trial misstatements. Affected investors have until March 16, 2026 deadline to seek lead plaintiff status or secure counsel.
VTGNPhase 3 clinical trialsecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Vistagen Faces Class Action Lawsuit Over Failed Trial, Stock Crashes 80%

Class action lawsuit filed against Vistagen Therapeutics after Phase 3 trial failure causes 80% stock plunge. Investors have until March 16, 2026 deadline.
VTGNclass action lawsuitmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Faces Securities Lawsuit Over Fasedienol Drug Claims

Vistagen Therapeutics faces securities lawsuit over alleged fasedienol misstatements. Investors who purchased VTGN stock April 2024-December 2025 may be eligible for compensation; lead plaintiff deadline is March 16, 2026.
VTGNPhase 3 clinical trialsecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Therapeutics Faces Securities Class Action Over Drug Trial Disclosure Allegations

Rosen Law Firm announces March 16, 2026 deadline for investors to join securities class action against Vistagen Therapeutics ($VTGN) over alleged misleading statements regarding fasedienol drug trial.
VTGNsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Vistagen Investors Face Class Action Deadline Following Failed Phase 3 Trial

Vistagen faces class action lawsuit after Phase 3 trial failure for anxiety drug. Stock plunged 80%. Investors must act by March 16, 2026 deadline.
VTGNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Investors Face March Deadline in Securities Litigation Over Trial Disclosures

Vistagen faces securities lawsuit over misleading trial disclosures. Investors must nominate lead plaintiff by March 16, 2026 deadline.
VTGNsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Lawsuit Filed Against Vistagen Over Alleged Misstatements on Drug Trial

Class action lawsuit filed against Vistagen Therapeutics for alleged false statements regarding drug trial data. Investors who purchased securities April 2024-December 2025 may be eligible.
VTGNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Investors Face March Deadline in Securities Litigation Over Trial Disclosures

Vistagen investors face March 16, 2026 deadline in securities lawsuit alleging false statements about drug trials and clinical data that misled shareholders.
VTGNsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

Vistagen Faces Securities Fraud Lawsuit Over Failed Phase 3 Trial Results

Vistagen faces class action lawsuit for securities fraud after its Phase 3 trial failed, causing stock to plummet 80%. Investors allege misleading statements about trial progress.
VTGNsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Vistagen Securities Litigation: Investors Face March Deadline to Join Class Action

Vistagen faces securities class action over alleged misleading statements about drug fasedienol. Investors who purchased stock April 2024-December 2025 can join by March 16, 2026 deadline.
VTGNinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

Legal Action Deadline Set for Vistagen Investors Following Failed Trial

Vistagen's failed drug trial caused 81% stock drop. Securities lawsuit filed for investors who bought shares April 2024-December 2025. Lead plaintiff deadline: March 16, 2026.
VTGNsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Schall Law Firm Opens Class Action Against Vistagen Over PALISADE-2 Trial Disclosures

Schall Law Firm launches securities fraud class action against Vistagen for allegedly making misleading statements about fasedienol drug trial prospects, affecting investors from April 2024 to December 2025.
VTGNsecurities fraudclass action lawsuit